21st June 2022 | Pharma Updates

Aurobindo Pharma acquires 51% of GLS Pharma

The pharmaceutical company announced that its board of directors has approved the acquisition of a 51 percent stake in Hyderabad-based GLS Pharma for Rs 28.05 crore in cash.

CDSCO Joint Drug Controller detained by CBI in bribery case

In connection with a bribery investigation, Central Bureau of Investigation is conducting raids at the office of the Joint Drug Controller of the Central Drugs Standard Control Organization. The CBI stated that the raids were taking place in Delhi.

Pfizer acquire an 8.1 percent stake in Valneva, a French vaccines company

Pfizer has agreed to invest 90.5 million euros to acquire an 8.1 percent stake in a French vaccines company, as the companies announced new developments in their collaboration to combat Lyme disease.

Cadila Pharma launches a new formulation development lab

Cadila Pharma’s formulation development lab is inaugurated by an Ethiopian envoy. The Ethiopian Ambassador to India, Dr Tizita Mulugeta Yimam, inaugurates Cadila Pharma’s formulation development laboratory in Dholka, near Ahmedabad.

Vifor Pharma investigated by EU for antitrust violations

The European Commission announced that it has launched an antitrust investigation into Swiss pharmaceutical company Vifor Pharma AG to determine whether it restricted competition by illegally disparaging a competitor.

OrganaBio initiated contract cell therapy manufacturing operations

OrganaBio starts GMP manufacturing operations at its new cell therapy manufacturing facility, ushering in a new era of contract and development manufacturing for therapeutics developers.

Skyrizi by AbbVie becomes the first FDA-approved IL-23 inhibitor for Crohn's disease

USFDA has granted AbbVie’s Skyrizi the first approval in the specific interleukin-23 inhibitor space for Crohn’s disease. Skyrizi is now approved for use in adults with moderately to severely active Crohn’s disease.